Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestonePUBT·2 days ago, 03:17 PMVRXA-0.51%OABI-1.02%
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbUnusual Whales·2 days ago, 06:02 AMVRXA-0.51%OABI-1.02%
OmniAb files initial beneficial ownership statement for COO Amechi Ekeke NwachukuPUBT·Jul 13 at 07:08 AMOABI-1.02%
We're Not Very Worried About OmniAb's (NASDAQ:OABI) Cash Burn RateSimplywall·Jun 30 at 06:51 AMOABI-1.02%
OmniAb shareholders elect Cochran, Foehr as Class I directors at annual meetingPUBT·Jun 18 at 03:29 PMOABI-1.02%
OmniAb | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 14.43 MEarnings Watch·May 7 at 03:55 PMOABI-1.02%
